Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries

Angewandte Chemie - International Edition

Volumn 42, Issue 28, 2003, Pages 3251-3253

  Fujii, Nobutaka ^a   Oishi, Shinya ^a   Hiramatsu, Kenichi ^a   Araki, Takanobu ^a   Ueda, Satoshi ^a   Tamamura, Hirokazu ^a   Otaka, Akira ^a   Kusano, Shuichi ^b   Terakubo, Shigemi ^b   Nakashima, Hideki ^b   Broach, James A ^c   Trent, John O ^d   Wang, Zi xuan ^e   Peiper, Stephen C ^e  

^a KYOTO UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c PRINCETON UNIVERSITY   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antagonists; Antiviral agents; Drug design; High throughput screening; Peptides

Indexed keywords

CONFORMATIONS; LEAD COMPOUNDS;

MOLECULAR SIZE;

POLYPEPTIDES;

CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLO[3 (2 NAPHTHYL)ALANYLGLYCYL DEXTRO TYROSYLARGINYLARGININE]; CYCLOPEPTIDE; LIGAND; MACROCYCLIC COMPOUND; PENTAPEPTIDE; T140; UNCLASSIFIED DRUG;

ARTICLE; BETA SHEET; CONFORMATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; REDUCTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; OLIGOPEPTIDES; PEPTIDE LIBRARY; PEPTIDES, CYCLIC; PROTEIN CONFORMATION; RECEPTORS, CXCR4;

EID: 10744227507     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200351024     Document Type: Article

References (21)

1. For recent reviews of drug discovery from natural/unnatural peptides, see a) V. J. Hruby, P. M. Balse, Curr. Med. Chem. 2000, 7, 945;
2. b) N. Fujii, H. Tamamura, Curr. Opin. Invest. Drugs 2001, 2, 1198.
3. Cyclic oligopeptides, which are relatively constrained by a ring structure, have been successfully employed for designing nonpeptidic agents in medicinal chemistry, see a) T. Fukami, T. Nagase, K. Fujita, T. Hayama, K. Niiyama, T. Mase, S. Nakajima, T. Fukuroda, T. Saeki, M. Nishikibe, M. Ihara, M. Yano, K. Ishikawa, J. Med. Chem. 1995, 38, 4309; b) R. Haubner, R. Gratias, B. Diefenbach, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 118, 7461; c) A. F. Spatola, Y. Crozet, J. Med. Chem. 1996, 39, 3842; d) J. Wermuth, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1997, 119, 1328; e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374; f) K. Nakayama, H. C. Kawano, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3447; g) H. C. Kawano, K. Nakayama, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3451.
4. Cyclic oligopeptides, which are relatively constrained by a ring structure, have been successfully employed for designing nonpeptidic agents in medicinal chemistry, see a) T. Fukami, T. Nagase, K. Fujita, T. Hayama, K. Niiyama, T. Mase, S. Nakajima, T. Fukuroda, T. Saeki, M. Nishikibe, M. Ihara, M. Yano, K. Ishikawa, J. Med. Chem. 1995, 38, 4309; b) R. Haubner, R. Gratias, B. Diefenbach, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 118, 7461; c) A. F. Spatola, Y. Crozet, J. Med. Chem. 1996, 39, 3842; d) J. Wermuth, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1997, 119, 1328; e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374; f) K. Nakayama, H. C. Kawano, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3447; g) H. C. Kawano, K. Nakayama, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3451.
5. Cyclic oligopeptides, which are relatively constrained by a ring structure, have been successfully employed for designing nonpeptidic agents in medicinal chemistry, see a) T. Fukami, T. Nagase, K. Fujita, T. Hayama, K. Niiyama, T. Mase, S. Nakajima, T. Fukuroda, T. Saeki, M. Nishikibe, M. Ihara, M. Yano, K. Ishikawa, J. Med. Chem. 1995, 38, 4309; b) R. Haubner, R. Gratias, B. Diefenbach, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 118, 7461; c) A. F. Spatola, Y. Crozet, J. Med. Chem. 1996, 39, 3842; d) J. Wermuth, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1997, 119, 1328; e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374; f) K. Nakayama, H. C. Kawano, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3447; g) H. C. Kawano, K. Nakayama, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3451.
6. Cyclic oligopeptides, which are relatively constrained by a ring structure, have been successfully employed for designing nonpeptidic agents in medicinal chemistry, see a) T. Fukami, T. Nagase, K. Fujita, T. Hayama, K. Niiyama, T. Mase, S. Nakajima, T. Fukuroda, T. Saeki, M. Nishikibe, M. Ihara, M. Yano, K. Ishikawa, J. Med. Chem. 1995, 38, 4309; b) R. Haubner, R. Gratias, B. Diefenbach, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 118, 7461; c) A. F. Spatola, Y. Crozet, J. Med. Chem. 1996, 39, 3842; d) J. Wermuth, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1997, 119, 1328; e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374; f) K. Nakayama, H. C. Kawano, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3447; g) H. C. Kawano, K. Nakayama, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3451.
7. Cyclic oligopeptides, which are relatively constrained by a ring structure, have been successfully employed for designing nonpeptidic agents in medicinal chemistry, see a) T. Fukami, T. Nagase, K. Fujita, T. Hayama, K. Niiyama, T. Mase, S. Nakajima, T. Fukuroda, T. Saeki, M. Nishikibe, M. Ihara, M. Yano, K. Ishikawa, J. Med. Chem. 1995, 38, 4309; b) R. Haubner, R. Gratias, B. Diefenbach, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 118, 7461; c) A. F. Spatola, Y. Crozet, J. Med. Chem. 1996, 39, 3842; d) J. Wermuth, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1997, 119, 1328; e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374; f) K. Nakayama, H. C. Kawano, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3447; g) H. C. Kawano, K. Nakayama, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3451.
8. Cyclic oligopeptides, which are relatively constrained by a ring structure, have been successfully employed for designing nonpeptidic agents in medicinal chemistry, see a) T. Fukami, T. Nagase, K. Fujita, T. Hayama, K. Niiyama, T. Mase, S. Nakajima, T. Fukuroda, T. Saeki, M. Nishikibe, M. Ihara, M. Yano, K. Ishikawa, J. Med. Chem. 1995, 38, 4309; b) R. Haubner, R. Gratias, B. Diefenbach, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 118, 7461; c) A. F. Spatola, Y. Crozet, J. Med. Chem. 1996, 39, 3842; d) J. Wermuth, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1997, 119, 1328; e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374; f) K. Nakayama, H. C. Kawano, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3447; g) H. C. Kawano, K. Nakayama, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3451.
9. Cyclic oligopeptides, which are relatively constrained by a ring structure, have been successfully employed for designing nonpeptidic agents in medicinal chemistry, see a) T. Fukami, T. Nagase, K. Fujita, T. Hayama, K. Niiyama, T. Mase, S. Nakajima, T. Fukuroda, T. Saeki, M. Nishikibe, M. Ihara, M. Yano, K. Ishikawa, J. Med. Chem. 1995, 38, 4309; b) R. Haubner, R. Gratias, B. Diefenbach, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 118, 7461; c) A. F. Spatola, Y. Crozet, J. Med. Chem. 1996, 39, 3842; d) J. Wermuth, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1997, 119, 1328; e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374; f) K. Nakayama, H. C. Kawano, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3447; g) H. C. Kawano, K. Nakayama, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3451.
10. Cyclic oligopeptides, which are relatively constrained by a ring structure, have been successfully employed for designing nonpeptidic agents in medicinal chemistry, see a) T. Fukami, T. Nagase, K. Fujita, T. Hayama, K. Niiyama, T. Mase, S. Nakajima, T. Fukuroda, T. Saeki, M. Nishikibe, M. Ihara, M. Yano, K. Ishikawa, J. Med. Chem. 1995, 38, 4309; b) R. Haubner, R. Gratias, B. Diefenbach, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 118, 7461; c) A. F. Spatola, Y. Crozet, J. Med. Chem. 1996, 39, 3842; d) J. Wermuth, S. L. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1997, 119, 1328; e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374; f) K. Nakayama, H. C. Kawano, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3447; g) H. C. Kawano, K. Nakayama, H. Inagaki, T. Ohta, Org. Lett. 2001, 3, 3451.
11. a) H. Tamamura, A. Omagari, S. Oishi, T. Kanamoto, N. Yamamoto, S. C. Peiper, H. Nakashima, A. Otaka, N. Fujii, Bioorg. Med. Chem. Lett. 2000, 10, 2633;
12. b) H. Tamamura, M. Sugioka, Y. Odagaki, A. Omagari, Y. Kan, S. Oishi, H. Nakashima, N. Yamamoto, S. C. Peiper, N. Hamanaka, A. Otaka, N. Fujii, Bioorg. Med. Chem. Lett. 2001, 11, 359.
13. a) J. A. Burger, M. Burger, T. Kipps, Blood 1999, 94, 3658;
14. b) T. Nanki, K. Hayashida, H. S. El-Gabalawy, S. Suson, K. Shi, H. J. Girschick, S. Yavuz, P. E. Lipsky, J. Immunol. 2000, 165, 6590;
15. c) A. Müller, B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. Mcclanahan, E. Murphy, W. Yuan, S. M. Wagner, J. L. Barrera, A. Mohar, E. Verástegui, A. Zlotnik, Nature 2001, 410, 50;
16. d) M. K. Schwarz, T. N. C. Wells, Nat. Rev. Drug Discovery 2002, 1, 347.
17. An additional Gly residue was employed as a spacer to avoid epimerization of a C-terminal residue during cyclization in peptide synthesis.
18. The synthesis and evaluation of cyclic peptides are described in detail in the Supporting Information.
19. CXCR4 is known to participate in infection by X4-HIV virus,[9] and in our previous research the affinities of T140 derivatives for CXCR4 have correlated with the anti-HIV activity.
20. The principal concept of "sequence-based" libraries has been reported as the "spatial-screening" methodology: H. Kessler, B. Kutscher, R. Kerssebaum, A. Klein, J. Lautz in Peptides: Structures and Function, Proceedings of the Ninth American Peptide Symposium (Eds.: C. M. Deber, V. J. Hruby, K. Kopple), Pierce Chemical Company, Rockford, 1985, pp. 83-92; and reference [2b].
21. Y. Feng, C. C. Broder, P. E. Kennedy, E. A. Berger, Science 1996, 272, 872.